BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024.
Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
The company's lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.
Also Read: Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data.
In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while restoring healthy body composition and improving muscle function.
The company plans to assess azelaprag's potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 trials.
The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound by Eli Lilly And Co (NYSE:LLY), with topline results anticipated in the third quarter of 2025.
The second Phase 2 trial will assess azelaprag in combination with semaglutide, marketed as Wegovy by Novo Nordisk A/S (NYSE:NVO), with initiation expected in the first half of 2025.
BioAge also intends to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion.
The company is also developing orally available small-molecule brain-penetrant NLRP3 inhibitors for diseases driven by neuroinflammation and anticipates submitting an Investigational New Drug application for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 trial in the first half of 2026.
In February, BioAge Labs completed a Series D financing round of $170 million led by Sofinnova Investments.
專注於開發代謝性疾病療法的生物技術公司BioAge Labs Inc向美國證券交易委員會提交了一份文件，要求通過首次公開募股籌集高達1億美元的資金。
該公司成立於2015年，計劃在納斯達克上市，股票代碼爲BIOA。BioAge Labs 於 2024 年 5 月 31 日祕密提交。
高盛、摩根士丹利、傑富瑞和花旗是該交易的聯合賬簿管理人。沒有披露任何定價條款。
該公司的主要藥物Azelaprag是一種口服可用的小分子，在八項1期臨床試驗中，265人耐受性良好。
另請閱讀：新上市的肥胖公司Fractyl Health分享了令人鼓舞的臨床前數據。
在臨床前肥胖模型中，azelaprag證明了能夠使胰高血糖素樣肽1受體（GLP-1R）激動劑誘導的體重減輕一倍以上，同時恢復健康的身體成分和改善肌肉功能。
該公司計劃在兩項二期試驗中評估 azelaprag 與 GLP-1R 激動劑聯合使用可顯著改善體重的潛力。
正在進行的STRIDES臨床試驗將評估azelaprag與替塞帕肽的聯合使用，由禮來公司（紐約證券交易所代碼：LLY）以Zepbound的名義銷售，預計將在2025年第三季度取得主要結果。
第二階段試驗將評估阿澤拉普拉格與索瑪魯肽的聯合用途，由諾和諾德A/S（紐約證券交易所代碼：NVO）以Wegovy的名義銷售，預計將於2025年上半年啓動。
BioAge還打算在2025年上半年啓動azelaprag單一療法的胰島素敏感性概念驗證試驗，以支持潛在的適應症擴展。
該公司還在開發用於神經炎症驅動疾病的口服小分子腦穿透劑 NLRP3 抑制劑，預計將在2025年下半年提交 NLRP3 抑制劑的研究性新藥申請，如果獲得批准，將在2026年上半年啓動1期試驗。
2月，BioAge Labs完成了由Sofinnova Investments牽頭的1.7億美元D輪融資。
